Investor Contact: Austin Murtagh Precision AQ Austin.Murtagh@precisionAQ.com (212) 698-8696 Media Contact: DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 202 ...

公司动态 - 公司管理层将于6月5日上午10:30参加杰富瑞全球医疗保健会议的炉边谈话 [1] - 炉边谈话的直播和存档录像将在会议结束后90天内可在公司投资者关系网站上查看 [2] 公司介绍 - 公司是一家专注于变革药物以改善生活的生物制药公司 [1][3] - 公司采用创新解决方案开发药物以应对患者当前治疗选择面临的挑战 [3] - 公司商业产品LUMRYZ™获美国FDA批准，是首个也是唯一一种睡前服用一次的羟丁酸盐，用于治疗7岁及以上发作性睡病患者的猝倒或白天过度嗜睡 [3] 联系方式 - 投资者联系人为Austin Murtagh，邮箱Austin.Murtagh@precisionAQ.com，电话(212) 698-8696 [4] - 媒体联系人为Lesley Stanley，邮箱lestanley@realchemistry.com，电话(609) 273-3162 [4]

DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3 Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days foll ...

-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor ...

文章核心观点 公司将于2025年5月7日上午8点举办电话会议和网络直播，提供公司最新情况并讨论2025年第一季度财务结果 [1] 会议信息 - 可通过访问公司网站投资者关系板块收听直播 [2] - 网络直播回放将在活动结束后在公司网站存档90天 [2] - 参与者可在此处注册电话会议，建议提前至少10分钟注册 [2] 公司介绍 - 公司是一家生物制药公司，致力于变革药物以改善生活 [1][3] - 公司采用创新方案开发药物，解决患者现有治疗方案面临的挑战 [3] - 公司商业产品LUMRYZ™获美国FDA批准，是首个也是唯一一款睡前服用的羟丁酸盐，用于治疗7岁及以上发作性睡病患者的猝倒或白天过度嗜睡 [3] 联系方式 - 投资者联系人为Austin Murtagh，邮箱Austin.Murtagh@precisionAQ.com，电话(212) 698-8687 [4] - 媒体联系人为Lesley Stanley，邮箱lestanley@realchemistry.com，电话(609) 273-3162 [4]